Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders

Nephrology

Volumn 11, Issue 2, 2006, Pages 142-146

  Brewster, Ursula C ^a   Ciampi, Marc A ^a   Abu Alfa, Ali K ^a   Reilly, Robert F ^b,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

Calcium acetate; Metabolic acidosis; Renal osteodystrophy; Serum phosphorus; Sevelamer hydrochloride

Indexed keywords

BICARBONATE; CALCIUM ACETATE; CALCIUM CARBONATE; MAGNESIUM CARBONATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ADULT; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY DISEASE; LONG TERM CARE; MALE; MEDICAL RECORD; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

ACETATES; BICARBONATES; CALCIUM; CALCIUM CARBONATE; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MAGNESIUM; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; RETROSPECTIVE STUDIES;

EID: 33645880441     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00544.x     Document Type: Review

References (23)

1. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol. Dial. Transplant. 2003 18 Suppl. 3 2 8.
2. Block GA Hulbert-Shearon TE Levin NW Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 1998 31 607 17.
3. Ganesh SK Stack AG Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 2001 12 2131 8.
4. Slatopolsky E Weerts C Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. 1986 315 157 61.
5. Hercz G Kraut JA Andress DA et al. Use of calcium carbonate as a phosphate binder in dialysis patients. Miner. Electrolyte Metab. 1986 12 314 19.
6. Guerin AP London GM Marchais SJ Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 2000 15 1014 21.
7. Goodman WG Goldin J Kuizon BD et al. Coronary calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 2000 342 1478 83.
8. Qunibi WY Nolan CA Ayus JC. Cardiovascular calcification in patients with end-stage renal disease: A century-old phenomenon. Kidney Int. 2002 82 Suppl. 73 80.
9. Chertow GM Burke SK Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am. J. Kidney Dis. 1999 29 66 71.
10. Chertow GM Dillon M Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 1999 51 18 26.
11. Goldberg DI Dillon MA Slatopolsky EA et al. Effect of Renagel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol. Dial. Transplant. 1998 13 2303 10.
12. Slatopolsky EA Burke SK Dillon MA. Renagel, a nonabsorbed calcium- and aluminium-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int. 1999 55 299 307.
13. Bleyer AJ Burke AK Dillon MA et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. 1999 33 694 701.
14. Eknoyan G Levin A Levin NW. Bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003 42 1 201.
15. Freedman BI. Susceptibility genes for hypertension and renal failure. J. Am. Soc. Nephrol. 2003 14 Suppl. 2 S192 4.
16. Chertow GM Burke SK Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002 62 245 52.
17. Gallieni M Cozzolino M Brancaccio D. Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. 2000 57 1776 7.
18. Walters BA Delahunty MI Rojas C et al. Control of serum phosphate level by sevelamer hydrochloride may occur at the expense of lowering serum bicarbonate in hemodialysis patients. J. Am. Soc. Nephrol. 2002 13 586A.
19. Kraut JA. Disturbances of acid-base balance and bone disease in end-stage renal disease. Semin. Dial. 2000 13 261 6.
20. Bushinsky D. The contribution of acidosis to renal osteodystrophy. Kidney Int. 1995 47 1816 32.
21. Qunibi WY Hootkins RE McDowell LL et al. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 2004 65 1914 26.
22. Hervas JG Prados D Cerezo S. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: A comparison with calcium acetate. Kidney Int. 2003 63 S69 72.
23. Steitz SA Speer MY Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ. Res. 2001 89 1147 54.